While Bio-Rad Laboratories
What analysts say:
- Buy, sell, or hold?: Analysts strongly back Bio-Rad Laboratories, with four of five rating it a buy and the remainder rating it a hold. Analysts like Bio-Rad Laboratories better than competitor Gen-Probe overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $508.2 million in revenue this quarter. That would represent a rise of 8.7% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.47 per share. Estimates range from $1.45 to $1.48.
What our community says:
CAPS All Stars are solidly behind the stock, with 100% assigning it an "outperform" rating. The community at large concurs with the All Stars, with 96.2% awarding it a rating of "outperform." Fools are keen on Bio-Rad Laboratories, though the message boards have been quiet lately with only 61 posts in the past 30 days. Bio-Rad Laboratories has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
Bio-Rad Laboratories' profit has risen year over year by an average of 22.6%. Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Bio-Rad Laboratories now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.